Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Phase 1 Completed 19 enrolled Immorna Biotherapeutics, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

: A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors

Timeline

Start: 2023-02-24
Primary completion: 2024-09-30
Completion: 2024-09-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JCXH-211	Other / unclassified	—	Other

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Summary

Timeline

Drugs

Indications